BioSpace News Archive

Tanasi formulas including CBDA and CBD are patent-pending

Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors

A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the benefit of oral immunotherapy (OIT) for peanut allergy treatment and highlights the potential risks of allergy immunotherapy discontinuation.

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID™, a new, simple cheek swab that can be used by physicians to screen patients with chronic obstructive pulmonary disease (COPD) for alpha-1 antitrypsin deficiency (Alpha-1), a rare, life-threatening genetic condition.

Researchers at The Feinstein Institutes for Medical Research used new closed-loop neurostimulation methods and textile-based electrodes to facilitate individual finger movement and grasp force regulation in quadriplegia individuals.

Laurel Bridge Software announces the new Laurel Bridge AI Workflow Suite that enhances the ability of healthcare providers and AI developers to integrate artificial intelligence (AI) algorithms into their clinical workflows.

Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial

Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program

Checkpoint Therapeutics, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business update and reported its financial results for the quarter ended September 30, 2019.